Stay updated on Upadacitinib in Active Ankylosing Spondylitis Clinical Trial
Sign up to get notified when there's something new on the Upadacitinib in Active Ankylosing Spondylitis Clinical Trial page.

Latest updates to the Upadacitinib in Active Ankylosing Spondylitis Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedAn NIH website-transition announcement appears above the 403 Forbidden error, and the displayed site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check30 days agoChange DetectedThe footer site revision changed from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check44 days agoChange DetectedThe page now renders a 403 Forbidden error, making the study record inaccessible. This indicates an access issue rather than new content on the page.SummaryDifference19%

- Check51 days agoChange DetectedRevision tag updated from v3.6.6 to v3.7.0 on the page, indicating a new version of the page. This metadata change does not modify visible study details.SummaryDifference0.0%

- Check58 days agoChange DetectedA new publication citation was added to the study's Publications section, describing extramusculoskeletal manifestations in upadacitinib-treated patients with Psoriatic Arthritis or Axial Spondyloarthritis.SummaryDifference0.0%

- Check65 days agoChange DetectedThe page now shows Revision: v3.6.6, replacing the previous Revision: v3.6.5. This indicates a minor update to the page's build/metadata rather than any change to the study content.SummaryDifference0.0%

Stay in the know with updates to Upadacitinib in Active Ankylosing Spondylitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Upadacitinib in Active Ankylosing Spondylitis Clinical Trial page.